MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ehjopen/oeaf028

Медицинская библиотека · European heart journal open · 2025

Insulin-like growth factor binding protein-3 (IGFBP-3): a biomarker of coronary artery disease induced myocardial ischaemia.

Lee Jacqui A, Wise Jessika, Raudsepp Sara D, Paton Louise N, Powell Jan, Jina Kieran, Aldous Sally, Troughton Richard W, Adamson Philip D, Richards A Mark, Peacock W Frank, Januzzi James L, Erceg Noah, Koechlin Luca, Boeddinghaus Jasper, Lopez-Ayala Pedro, Mueller Christian, Than Martin P, Pickering John W, Pemberton Chris J

СтатьяПеревод в очереди

Аннотация

AIMS: Among individuals presenting to the emergency department (ED) with chest pain, clinical uncertainty surrounds the appropriate identification of non-myocardial infarction (MI) individuals who would most benefit from objective functional/anatomical testing (e.g. imaging). We applied a proteomic biomarker discovery approach to identify novel candidates reflecting coronary artery disease (CAD) induced ischaemia that could translate to measurement in clinical samples.

METHODS AND

RESULTS

Mass spectroscopy (MS) of perfusate from an isolated rat heart model of cardiac ischaemia identified >100 novel protein biomarkers. A prominent candidate, insulin-like growth factor binding protein (IGFBP-3), was then interrogated for its ability to identify CAD-related ischaemia (e.g. positive cardiac stress test; unstable angina pectoris, UAP; arterial stenosis >70% on angiography) in multiple patient sample sets [cardiac stress testing, n = 12; septal alcohol ablation (SAA), n = 12; ED chest pain, n = 2977]. In cardiac stress testing, a significant delta IGFBP-3 (ΔIGFBP-3) between 0 and 150 min was seen in positive, but not negative, tests (P = 0.03). In SAA, peripheral IGFBP-3 levels did not change over 24 h (P = 0.57). In ED patients, ΔIGFBP-3 between 0 and 2 h (i) identified more 365-day low-risk major adverse cardiac event cases (27-30%), (ii) provided 7% improvement in positive predictive value over a clinical model for the identification of unstable angina (P = 0.01), and (iii) was a significant, independent predictor of >70% stenosis on angiography, improving indeterminate risk prediction by 9% (95% CI 3-15%).

CONCLUSION

Our discovery approach has translated IGFBP-3 as a potential biomarker to identify significant CAD/ischaemia in patients who do not meet diagnostic thresholds for MI.

Для цитирования: Lee Jacqui A, Wise Jessika, Raudsepp Sara D, Paton Louise N, Powell Jan, Jina Kieran, Aldous Sally, Troughton Richard W, Adamson Philip D, Richards A Mark, Peacock W Frank, Januzzi James L, Erceg Noah, Koechlin Luca, Boeddinghaus Jasper, Lopez-Ayala Pedro, Mueller Christian, Than Martin P, Pickering John W, Pemberton Chris J. Insulin-like growth factor binding protein-3 (IGFBP-3): a biomarker of coronary artery disease induced myocardial ischaemia.. European heart journal open. 2025. DOI: 10.1093/ehjopen/oeaf028.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.